CABACabaletta Bio, Inc.

Nasdaq www.cabalettabio.com


$ 17.13 $ 0.19 (1.12 %)    

Wednesday, 27-Mar-2024 15:59:57 EDT
QQQ $ 444.97 $ 1.51 (0.34 %)
DIA $ 397.57 $ 4.71 (1.2 %)
SPY $ 523.27 $ 4.36 (0.84 %)
TLT $ 94.66 $ 0.93 (0.99 %)
GLD $ 203.04 $ 1.46 (0.72 %)
$ 17.15
$ 16.96
$ 0.00 x 0
$ 17.15 x 200
$ 16.60 - $ 17.14
$ 6.94 - $ 26.35
987,834
na
827.34M
$ 1.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-16-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 11-01-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-03-2021 03-31-2021 10-Q
13 03-16-2021 12-31-2020 10-K
14 11-10-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-12-2020 03-31-2020 10-Q
17 03-30-2020 12-31-2019 10-K
18 12-05-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cabaletta-bio-issued-idnct06328777-for-phase-12-open-label-study-to-evaluate-the-safety-and-efficacy-of-caba-201-a-cd19-car-t-cell-therapy-in-subjects-with-systemic-sclerosis-posted-to-clinical-trials-website-on-2024-03-25-study-is-not-yet-recruiting

https://clinicaltrials.gov/study/NCT06328777   Inclusion Criteria:

 cantor-fitzgerald-reiterates-overweight-on-cabaletta-bio-maintains-50-price-target

Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...

 wells-fargo-maintains-overweight-on-cabaletta-bio-raises-price-target-to-35

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $...

 hc-wainwright--co-maintains-buy-on-cabaletta-bio-raises-price-target-to-30

HC Wainwright & Co. analyst Douglas Tsao maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target fr...

 recap-cabaletta-bio-q4-earnings
Recap: Cabaletta Bio Q4 Earnings
03/21/2024 13:10:06

 cabaletta-bio-inc-files-for-mixed-shelf-offering-size-not-disclosed

- SEC Filing

 cabaletta-bio-q4-eps-046-misses-039-estimate-cabaletta-had-cash-cash-equivalents-and-short-term-investments-of-2412m-expected-to-fund-its-operating-plan-into-the-first-half-of-2026

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.3...

 cramer-this-reit-is-a-little-too-dicey-as-for-marathon-digital-own-the-pure

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding onto Regions Financial Corporation (NYSE: RF).

 jefferies-initiates-coverage-on-cabaletta-bio-with-buy-rating-announces-price-target-of-36

Jefferies analyst Kelly Shi initiates coverage on Cabaletta Bio (NASDAQ:CABA) with a Buy rating and announces Price Target o...

 cabaletta-bio-gets-additional-fda-fast-track-designations-for-caba-201-in-dermatomyositis-and-systemic-sclerosis

To date, Cabaletta has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple...

 verint-reports-strong-earnings-joins-semtech-alphabet-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday.

 morgan-stanley-maintains-overweight-on-cabaletta-bio-lowers-price-target-to-25

Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from ...

 analyst-ratings-for-cabaletta-bio
Analyst Ratings for Cabaletta Bio
11/29/2023 12:00:31

 hc-wainwright--co-reiterates-buy-on-cabaletta-bio-maintains-25-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $25 price target.

 leslies-posts-weak-earnings-joins-las-vegas-sands-verve-therapeutics-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session

U.S. stock futures traded higher this morning, with the Dow Jones futures gaining around 100 points on Wednesday.

 crude-oil-surges-2-tharimmune-shares-plummet

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Tuesday. The Dow tr...

 why-senestech-shares-are-trading-lower-by-around-50-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION